Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. Read the article here.
Faster genomic sequencing and other tools are hastening the development of new diagnostic and prognostic tools for prostate cancer. Read the article here.
Emerging Therapies for Prostate Cancer Read More »
Multiparametric magnetic resonance imaging (MP-MRI) can accurately predict adverse pathologic features at the time of radical prostatectomy (RP) for localized prostate cancer, data presented at the 2018 Genitourinary Cancers Symposium suggest. Read the article here.
Adverse Prostate Cancer Pathology Accurately Predicted With MRI Read More »
A comparison of current commercially available liquid biopsies designed to conduct genetic testing of cDNA as a guide to the selection of drug therapy for men with advanced prostate cancer. Read the article here.
Commercially available liquid biopsy data may be misleading. Read More »
Prof. Gomella’s lecture is highly informative for the interested prostate cancer patient and prostate cancer advocate. The lecture is approximately 26 minutes long and really brings anyone who has an interest in the topic to a current state. Watch the video here.
Genomic Testing and Hereditary Prostate Cancer Read More »
Researchers at the Technical University of Munich have discovered they can predict drug resistance in patients with advanced prostate cancer using a new blood test. Read the article here.
New test to combat drug resistant cancer Read More »
Magnetic resonance imaging (MRI) of the prostate may be used in many clinical scenarios, including primary screening, active surveillance, and in patients with a previous negative biopsy and rising PSA. Scott Eggener, MD, explains whether MRI is warranted in each of these situations and the benefits and challenges this technology presents. Read the article here.
A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures – distinguishing cancer from benign conditions, and identifying patients with high-risk disease. Read the article here.
New IsoPSA assay detects prostate cancer more precisely than current tests Read More »
Researchers are developing genetic tests, imaging tests, and algorithms like those in face-recognition software in an effort to reduce the 1 million US men a year who have prostate biopsies and, even more important, reduce the thousands who get treatment they don’t need. Read the article here.
Thousands of men with prostate cancer get risky treatment they don’t need. Read More »
BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. Men with harmful BRCA1 or BRCA2 mutations have a higher risk of prostate cancer. A Toronto Women’s College Hospital research study, The Screen Project, provides Canadians access to affordable population-based genetic testing for the BRCA gene mutation. Watch the video here.
Genetic test for BRCA1/2 Read More »